Alps Advisors Inc. Has $1.37 Million Position in Impax Laboratories Inc (IPXL)

Alps Advisors Inc. boosted its position in shares of Impax Laboratories Inc (NASDAQ:IPXL) by 12.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 82,126 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,940 shares during the period. Alps Advisors Inc.’s holdings in Impax Laboratories were worth $1,367,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio grew its position in Impax Laboratories by 12.7% during the second quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock valued at $111,000 after buying an additional 780 shares during the period. TIAA CREF Investment Management LLC grew its position in Impax Laboratories by 1.0% during the second quarter. TIAA CREF Investment Management LLC now owns 238,473 shares of the specialty pharmaceutical company’s stock valued at $3,839,000 after buying an additional 2,463 shares during the period. Voya Investment Management LLC grew its position in Impax Laboratories by 7.9% during the second quarter. Voya Investment Management LLC now owns 33,947 shares of the specialty pharmaceutical company’s stock valued at $547,000 after buying an additional 2,499 shares during the period. California Public Employees Retirement System grew its position in Impax Laboratories by 2.2% during the second quarter. California Public Employees Retirement System now owns 114,900 shares of the specialty pharmaceutical company’s stock valued at $1,850,000 after buying an additional 2,500 shares during the period. Finally, American International Group Inc. grew its position in Impax Laboratories by 5.9% during the third quarter. American International Group Inc. now owns 58,242 shares of the specialty pharmaceutical company’s stock valued at $1,182,000 after buying an additional 3,233 shares during the period. Institutional investors own 91.54% of the company’s stock.

Several analysts recently commented on the stock. BidaskClub lowered shares of Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. UBS Group lifted their target price on shares of Impax Laboratories from $12.00 to $16.00 and gave the company a “sell” rating in a research report on Monday, October 30th. Cantor Fitzgerald set a $35.00 target price on shares of Impax Laboratories and gave the company a “buy” rating in a research report on Friday, December 15th. Canaccord Genuity set a $19.00 target price on shares of Impax Laboratories and gave the company a “hold” rating in a research report on Tuesday, October 17th. Finally, Leerink Swann assumed coverage on shares of Impax Laboratories in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 target price on the stock. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.62.

Impax Laboratories Inc (NASDAQ:IPXL) opened at $19.52 on Friday. The firm has a market cap of $1,430.00, a PE ratio of -3.12, a P/E/G ratio of 0.99 and a beta of 1.11. Impax Laboratories Inc has a 52-week low of $7.75 and a 52-week high of $25.70. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.32 and a current ratio of 1.81.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. The firm had revenue of $206.40 million for the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. Impax Laboratories’s quarterly revenue was down 9.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.37 earnings per share. analysts anticipate that Impax Laboratories Inc will post 0.64 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Alps Advisors Inc. Has $1.37 Million Position in Impax Laboratories Inc (IPXL)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.com-unik.info/2018/02/10/alps-advisors-inc-has-1-37-million-position-in-impax-laboratories-inc-ipxl.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories Inc (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit